Identification Of A Pharmacodynamic Biomarker For Sel24/Men1703, A First-In-Class Dual Pim/Flt3 Kinase Inhibitor For Acute Myeloid Leukemia, And Its Implementation In The First-In-Human Study Cli24-001

Andrea Tomirotti,Giuseppe Merlino,Alessio Fiascarelli,Simone Baldini,Alessia Tagliavini, Elisa Borella,Milena Mazan,Krzysztof Brzózka,Alessandro Bressan,Andrea Pellacani,Massimiliano Salerno,Monica Binaschi,Daniela Bellarosa

BLOOD（2019）

引用 0|浏览7

暂无评分

摘要

SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 kinase inhibitor currently investigated in patients with Acute Myeloid Leukemia (AML) in the first-in-human study CLI24-001 (NCT03008187).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要